AbCellera Biologics Inc. announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. Lilly’s Phase 3 BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN). Key details from the BLAZE-2 study are as follows: Participants were grouped based on their COVID-19 status at baseline: 965 COVID-19 negative participants (299 residents and 666 staff) were in the prevention group, and 132 COVID-19 positive participants (41 residents and 91 staff) were in the treatment group; b Participants in each group were randomized to receive either 4,200 mg of bamlanivimab or placebo; Serious adverse events were reported at a similar frequency in both placebo and bamlanivimab groups, consistent with previous safety observations in Phase 1 and Phase 2 trials; Bamlanivimab reduced the risk of contracting COVID-19 by up to 80% in residents versus placebo (odds ratio 0.20; p=0.00026); and All deaths attributed to COVID-19 occurred in residents receiving the placebo. There were no COVID-19-related deaths of participants receiving bamlanivimab.